Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002392
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
Sponsor:
Rockefeller University
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy
Status:
COMPLETED
Status Verified Date:
1999-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients particularly on markers of immune activation and parameters of specific anti-HIV cellular immunity
Detailed Description:
Patients receive oral thalidomide in a blinded placebo-controlled study AS PER AMENDMENT 112598 This is a double-blind placebo-controlled trial in which thalidomide or placebo is administered for 21 days After the first week of therapy patients receive immunizations with keyhole limpet hemocyanin and polyvalent pneumococcal vaccine Study therapy is stopped for 2 weeks after the immunizations Following the immunizations detailed evaluations of the immune responses to the vaccines are conducted over the next 8 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: